235 related articles for article (PubMed ID: 19079316)
1. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.
Hebart H; Klingspor L; Klingebiel T; Loeffler J; Tollemar J; Ljungman P; Wandt H; Schaefer-Eckart K; Dornbusch HJ; Meisner C; Engel C; Stenger N; Mayer T; Ringden O; Einsele H
Bone Marrow Transplant; 2009 Apr; 43(7):553-61. PubMed ID: 19079316
[TBL] [Abstract][Full Text] [Related]
2. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.
Wingard JR; White MH; Anaissie E; Raffalli J; Goodman J; Arrieta A;
Clin Infect Dis; 2000 Nov; 31(5):1155-63. PubMed ID: 11073745
[TBL] [Abstract][Full Text] [Related]
6. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.
Blennow O; Remberger M; Klingspor L; Omazic B; Fransson K; Ljungman P; Mattsson J; Ringdén O
Bone Marrow Transplant; 2010 Dec; 45(12):1710-8. PubMed ID: 20190840
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
[TBL] [Abstract][Full Text] [Related]
8. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
[TBL] [Abstract][Full Text] [Related]
9. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
[TBL] [Abstract][Full Text] [Related]
10. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
Kolve H; Ahlke E; Fegeler W; Ritter J; Jürgens H; Groll AH
J Antimicrob Chemother; 2009 Aug; 64(2):383-7. PubMed ID: 19491205
[TBL] [Abstract][Full Text] [Related]
12. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Dellow E; Herbrecht R; Donnelly JP
Mycoses; 2011 Sep; 54(5):e449-55. PubMed ID: 21039936
[TBL] [Abstract][Full Text] [Related]
13. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
Tollemar J; Ringdén O; Andersson S; Sundberg B; Ljungman P; Tydén G
Bone Marrow Transplant; 1993 Dec; 12(6):577-82. PubMed ID: 8136741
[TBL] [Abstract][Full Text] [Related]
14. A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India.
Jadhav MP; Shinde VM; Chandrakala S; Jijina F; Menon H; Arora B; Kurkure PA; Parikh PM; Kshirsagar NA
Indian J Cancer; 2012; 49(1):107-13. PubMed ID: 22842177
[TBL] [Abstract][Full Text] [Related]
15. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
Shah T; Lai WK; Gow P; Leeming J; Mutimer D
Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
[TBL] [Abstract][Full Text] [Related]
16. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders.
Hovi L; Saxen H; Saarinen-Pihkala UM; Vettenranta K; Meri T; Richardson M
Pediatr Blood Cancer; 2007 Jan; 48(1):28-34. PubMed ID: 16395687
[TBL] [Abstract][Full Text] [Related]
17. Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B.
Krüger WH; Kröger N; Rüssmann B; Renges H; Kabisch H; Zander AR
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S10-3. PubMed ID: 9916623
[TBL] [Abstract][Full Text] [Related]
18. Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT.
Hebart H; Lengerke C; Ljungman P; Paya CV; Klingebiel T; Loeffler J; Pfaffenrath S; Lewensohn-Fuchs I; Barkholt L; Tomiuk J; Meisner C; Lunenberg J; Top B; Razonable RR; Patel R; Litzow MR; Jahn G; Einsele H
Bone Marrow Transplant; 2011 Mar; 46(3):408-15. PubMed ID: 20581879
[TBL] [Abstract][Full Text] [Related]
19. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
20. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
